Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
16.93
0.00 (0.00%)
Sep 16, 2025, 11:27 AM EDT - Market open
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $81.50M in the quarter ending June 30, 2025, with 164.13% growth. This brings the company's revenue in the last twelve months to $263.47M, up 99.50% year-over-year. In the year 2024, Arcutis Biotherapeutics had annual revenue of $196.54M with 229.74% growth.
Revenue (ttm)
$263.47M
Revenue Growth
+99.50%
P/S Ratio
8.07
Revenue / Employee
$770,365
Employees
342
Market Cap
2.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 196.54M | 136.94M | 229.74% |
Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
Dec 31, 2022 | 3.69M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ARQT News
- 2 hours ago - Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award - GlobeNewsWire
- 6 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 10 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 12 days ago - Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 - GlobeNewsWire
- 24 days ago - Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate - Seeking Alpha
- 27 days ago - Arcutis to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript - Seeking Alpha